Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03532490 · ClinicalTrials.gov registry record · Phase 2

Trial of Roflumilast in Asthma Management (TRIM)

A Phase 2 study of Obesity and Asthma, sponsored by Johns Hopkins University.

Completed
Registry status
Phase 2
Development phase
38
Enrollment target
7
Study locations

NCT03532490: Completed Phase 2 study of Obesity and Asthma, sponsored by Johns Hopkins University.

NCT03532490 is a Phase 2 study of Obesity and Asthma that has completed, run by Johns Hopkins University. The registered enrollment target is 38 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03532490, a Phase 2 study of Obesity and Asthma, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
Phase 2
Development phase
38 participants
Enrollment target
7
Study locations

Study Summary

There are currently no treatments to specifically target asthma in obese adults. This pilot study is being conducted to investigate how effective roflumilast is in treating asthma in participants that have a higher BMI. Roflumilast can induce weight loss, which may lead to improved asthma control. The primary objective of TRIM is to perform a pilot placebo-controlled trial of roflumilast for the treatment of poorly controlled obese asthmatics.

Conditions Studied

Obesity Asthma

Interventions

  • DRUG Placebo oral capsule
  • DRUG Roflumilast 500 Mcg Oral Tablet

Study Locations (7)

Illinois

  • University of Illinois at Chicago, Breathe Chicago Center - Chicago
  • Northwestern University Feinberg School of Medicine - Chicago

Alabama

  • University of Alabama Lung Health Center - Birmingham

Arizona

  • University of Arizona - Tucson

New York

  • Mount Sinai Icahn School of Medicine - New York

North Carolina

  • Duke University - Durham

Vermont

  • University of Vermont - Colchester

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2018-08-03
Est. Completion 2021-07-30
Phase Phase 2

Sponsor

Johns Hopkins University

1,448 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03532490

The ClinicalTrials.gov registry entry for NCT03532490 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.

NCT03532490 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT03532490 about?

NCT03532490 is a clinical study titled "Trial of Roflumilast in Asthma Management (TRIM)". There are currently no treatments to specifically target asthma in obese adults. This pilot study is being conducted to investigate how effective roflumilast is in treating asthma in participants that have a higher BMI. Roflumilast can induce weight loss, which may lead to improved asthma control. ...

What is the current status of trial NCT03532490?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2018-08-03. Estimated completion is 2021-07-30.

What conditions does trial NCT03532490 study?

This clinical trial studies the following conditions: Obesity, Asthma.

What interventions are being tested in trial NCT03532490?

The interventions under investigation include: Placebo oral capsule (DRUG), Roflumilast 500 Mcg Oral Tablet (DRUG).

Who is sponsoring clinical trial NCT03532490?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03532490 being conducted?

This trial has 7 study locations across Alabama, Arizona, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Asthma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.